BioCentury | Jul 18, 2005
Clinical News

Duragesic fentanyl regulatory update

...only in opioid-tolerant patients, misuse, abuse and diversion, hypoventilation (respiratory depression), interactions with CYP3A4 ( cytochrome P450 3A4 mRNA...
BioCentury | Mar 22, 2004
Clinical News

AVI-4557: Phase Ib data

...on day 6. AVI BioPharma Inc. (AVII), Portland, Ore. Product: AVI-4557 Business: Neurology Molecular target: Cytochrome P450 3A4 mRNA...
BioCentury | Oct 20, 2003
Clinical News

AVI-4557: Phase I

...Inc. (AVII), Portland, Ore. Product: AVI-4557 Business: Neurology Molecular target: Cytochrome P450 3A4 mRNA Description: Antisense compound against cytochrome P450 3A4 mRNA...
BioCentury | Feb 24, 2003
Clinical News

AVI-4557 Neugene: Phase I

...AVII), Portland, Ore. Business: Metabolism Product: AVI-4557 Neugene Description: Antisense compound against cytochrome P450 3A4 mRNA Molecular target: Cytochrome P450 3A4 mRNA...
BioCentury | Feb 24, 2003
Clinical News

AVI-4557 Neugene: Phase I

...AVII), Portland, Ore. Product: AVI-4557 Neugene Business: Metabolism Molecular target: Cytochrome P450 3A4 mRNA Description: Antisense compound against cytochrome P450 3A4 mRNA...
Items per page:
1 - 5 of 5